The effects of repetitive transcranial magnetic stimulation on sleep in individuals with substance use disorders: A systematic review.

J Psychiatr ResJun 26, 2026 (epub)
Clinical ResearchPsychiatry

Anna Mouzenian, Daniel Felsky, Tesam Ahmed et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the effects of repetitive transcranial magnetic stimulation (rTMS) on sleep in individuals with substance use disorders (SUDs). Among twelve studies analyzed, ten reported significant sleep improvements following rTMS, particularly with protocols involving ≥10 sessions targeting the left dorsolateral prefrontal cortex. The findings highlight the potential of rTMS to enhance sleep in this population.

Key findings

  • Ten out of twelve studies reported statistically significant sleep improvements after rTMS.
  • Common parameters included stimulation of the left dorsolateral prefrontal cortex and protocols delivering ≥10 sessions.
  • Most studies focused on individuals with methamphetamine or cocaine use disorder.
  • All studies utilized subjective measures for assessing sleep outcomes.

Why it matters

Improving sleep in individuals with substance use disorders is essential, as sleep disturbances can increase relapse risk and negatively impact treatment outcomes. rTMS may offer a novel approach to address these issues.

Source

PubMed · PMID 42372632

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.